Comparative Pharmacology
Head-to-head clinical analysis: DEPEN versus PENICILLAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPEN versus PENICILLAMINE.
DEPEN vs PENICILLAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.
Chelates heavy metals (copper, mercury, lead, arsenic) forming soluble complexes excreted renally; also reduces cystine formation in cystinuria by disulfide exchange; immunosuppressive effects via inhibition of T-cell function and collagen synthesis.
250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.
250-500 mg orally 4 times daily, with a maximum of 2 g/day; for rheumatoid arthritis, initial dose 125-250 mg/day, increase by 125-250 mg every 1-3 months to usual maintenance of 500-750 mg/day in divided doses.
None Documented
None Documented
Clinical Note
moderatePenicillamine + Digoxin
"The serum concentration of Digoxin can be decreased when it is combined with Penicillamine."
Clinical Note
moderatePenicillamine + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Penicillamine."
Clinical Note
moderatePenicillamine + Eltrombopag
"The serum concentration of Eltrombopag can be increased when it is combined with Penicillamine."
Clinical Note
moderatePenicillamine + Iron
1.5-4 hours; prolonged to 6-12 hours in renal impairment; clinical context: dosing interval adjustments needed in CKD.
Terminal half-life: 1.5–2 hours for penicillamine; after chronic dosing, a slower phase (t1/2 ~40 hours) appears due to tissue binding. Clinical context: Dosing interval typically 6–8 hours; accumulation may occur in renal impairment.
Renal: 50% as unchanged drug; biliary/fecal: minor, <5%.
Renal: ~80% as unchanged drug and metabolites; fecal: ~20% (via biliary elimination).
Category C
Category C
Chelating Agent
Chelating Agent
"Penicillamine can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy."